Early Detection,
Better Outcomes.

Guided Therapeutics, Inc. (OTC: QB GTHP) is committed to developing groundbreaking medical devices using our patented biophotonic technology to detect diseases earlier, more accurately, and more efficiently than other tests.

Luviva

Product Information

Our products are designed to improve the patient’s experience, provide the physician with more powerful tools, improve the efficiency of the healthcare system and increase shareholder value.

How we are making
a difference globally

We are the maker of rapid and painless testing platform. The LuViva uses artificial intelligence (AI) to identify the key spectral components diagnostic of developing cancer.

Our products are designed to:

P

Improve the patient’s experience.

P

Provide the physician with more powerful tools.

P

Improve the efficiency of the healthcare system.

Technology

Our patented technology, which features our flagship product the LuViva® Advanced Cervical Scan, uses biophotonics to detect both physical and chemical changes in tissues that are early signs of cancer.

Technology
chart
Luviva

Investors

Cancer screening is a compelling market opportunity proven to save lives. As a pioneering company in this space, GTI represents an excellent investment.

Join our network of Investors

We are actively seeking new investors to join our network. We provide full transparency into our organization and would love to have you join.

 

We’re international and expanding. Read about Guided Therapeutics

Recent Press Releases

Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of LuViva

Nov 09, 2022

Guided Therapeutics Closes $3.3 Million Bridge Financing

Sep 07, 2022

Guided Therapeutics Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan

Jul 20, 2022

Guided Therapeutics Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740

Mar 31, 2022